PENGGUNAAN NANOPARTIKEL EMAS DALAM TEKNOLOGI UNTUK DIAGNOSIS KANKER

NADA FADHILAH

Abstract


ABSTRAK

Hingga saat ini kanker masih menjadi masalah kesehatan di berbagai Negara di dunia termasuk di Indonesia. Akhir-akhir ini sedang banyak dilakukan penelitian tentang penggunaan teknologi nanopartikel emas untuk mendiagnosis dan juga untuk penatalaksanaan penyakit kanker. Nanopartikel merupakan suatu bentuk material biologis dan sintetik yang dimensinya < 1 µm. fokus pada penelitian ini ialah dilakukan konjugasi antara modifikasi scFv dengan nanopartikel emas untuk mengembangkan immonusensor kolorimetri yang spesifik. Target yang digunakan ialah antibodi (IgG kelinci). Setelah dilakukan penambahan IgG kelinci, larutan uji berubah warna dari merah ke ungu muda akibat adanya agregasi yang terbentuk. Berdasarkan agregasi tersebut, konjugasi modifikasi scFv dengan nanopartikel emas menunjukkan sensitivitas yang baik. Oleh karena itu, teknologi ini dapat digunakan untuk analisis protein dan diagnostik klinis.

Kata kunci: Nanopartikel, Kanker, Konjugasi, Immunoassay

ABSTRACT

Until now, cancer is still a health problem in various countries in the world including in Indonesia. Lately there is a lot of research about the use of gold nanoparticle technology to diagnose and also for the management of cancer. Nanoparticles are all forms of biological and synthetic materials whose dimensions are <1 μm. The focus of this study was to do a conjugation between modification of scFv and gold nanoparticles to develop a specific colorimetric immunosensor. The target used is antibodies (rabbit IgG). After the addition of rabbit IgG, the test solution changes color from red to purple due to aggregation that is formed. Based on the aggregation, the conjugation of scFv modification with gold nanoparticles shows good sensitivity. Therefore, this technology can be used for protein analysis and clinical diagnostics.

Keyword: Nanoparticle, Cancer, Conjugation, Immunoassay

References


Artini, I. A. (2013). Peranan Nanopartikel dalam Penatalaksanaan Kanker di Era Targeting Therapy. Indonesian Journal of Cancer, Vol. 7, No. 3.

Bawarski, W. E., Chidlowsky, E., Bharali, D. J., & Mousa, S. A. (2008). Review Article: Pharmacology, Emerging Nanopharmaceutical. Nanomedicine: Nanotechnology, Biology, and Medicine 4, 273-282.

Buzea, C., Blandino, I. I., & Robbie, K. (2007). Nanomaterials and Nanoparticles: Sources and toxicity. Biointerphases, Vol. 2, Issue 4, MR17-MR172.

Dewi, G. T., & Hendrati, L. Y. (2015). Analisis Resiko Kanker Paayudara berdasarkan Riwayat Pemakaian Kontrasepsi Hormonal dan Usia Menarche. Epidemiologi, Vol. 3, No. 1.

Gibbs, J. B. (2000). Mechanism-Based target Identification and Drug Discovery in Cancer Research. Science.

Halid, N. A., & et al. (2017). Profil Klirens Konjugat Nanopartikel Emas Radioaktif (198Au)-poliamidoamin Generasi 4-nimotuzumab: Radiofarmaka Potensial sebagai Agen Theranostic. Pharmaciana, Vol. 7, No. 2, ISSN: 2088-4559, e-ISSN: 2477-0256, 239-248.

Inggriani, A. S., & Husni, P. (2017). Artikel Review: Formulasi Nanopartikel untuk Terapi Kanker. Farmaka, Vol. 14, No. 1, 127-135.

Johnson, E., Seachrist, D. D., DeLeon-Rodriguez, C. M., Lozada, K. L., Miedler, J., Abdul-Karim, F. W., et al. (2010). HER2/ErbB2-induced Breast Cancer Cell Migration and Invasion Require p120 Catenin Activation of Rac1 and Cdc42. Journal of Biological Chemistry, 285(38): 29491-29501.

Liu, Y., Liu, Y., Mernaugh, R. L., & Zeng, X. (2009). Single Chain Fragment Variable Recombinant Antibody Functionalized Gold Nanoparticles for a Highly Sensitive Colorimetric Immunoassay. Biosensors and Bioelectronics, 24, 2853-2857.

Martien, R., Adhyatmika, Irianto, I. D., Farida, V., & Sari, D. P. (2012). Perkembangan Teknologi Nanopartikel sebagai Sistem Penghantaran Obat. Majalah Farmaseutik, Vol.8, No. 1, 133-144.

Merisko-Liversidge, E. M., & Liversidge, G. G. (2008). Drug Nanoparticles: Formulating Poorly Water-Soluble Compounds. Toxicologic Pathology, 36, ISSN: 0192-6233, e-ISSN: 1533-1601, 43-48.

Nie, S. (2010). Understanding and Overcoming Major Barriers in Cancer Nanomedicine. Nanomedicine (Lond.), 5(4).

Peterson, E., Owens, S. M., & Henry, R. L. (2006). Monoclonal Antibody form and Function: Manufacturing The Right Antibodies for Treating Drug Abuse. AAPS Journal, 8(2): E383-E390.

Pohlmann, P. R., & Mernaugh, R. (2009). Resistance to Trastuzumab in Breast Cancer. Clinical Cancer Research, 15(24): 7479-7491.

Sastyarina et al. (2017). Kajian Dendrimer (Poly)amidoamine (PAMAM) Generasi 4 sebagai Template dalam Pembentukan Nanopartikel secara In Silico. Journal of Tropical Pharmacy and Chemistry, Vol. 4, No. 1, p-ISSN: 2087--7099, e-ISSN: 2407-6090.

Shen et al. (2005). Engineered Recombinant Single Chain Fragment Variable Antibodi For Immonosensors. Anal Chem, 77(21): 6834-6842.

Short, J. M., Waldron, R. A., Boyle, W., Chang, C., Anderson, C., Melnick, M., et al. (2005). Antibody Structure. Bioatla, 1-4.

Sihombing, M., & Sapardin, A. N. (2014). Faktor Risiko Tumor Payudara pada Perempuan Umur 25-65 tahun di Lima Kelurahan Kecamatan Bogor Tengah. Jurnal Kesehatan Reproduksi, ISSN: 2087-703X, eISSN: 2354-8762.

Spector, N., Xia, W., El-Hariry, I., Yarden, Y., & Bacus, S. (2007). Review: HER2 Therapy. Small Molecule HER-2 Tyrosine Kinase Inhibitors. Breast Cancer Research, 9(2):205.

Zeng, X., Shen, Z., & Mernaugh, R. (2012). Recombinant Antibodies and Their Use in Biosensors. Anal Bioanal Chem, 402(10): 3027-3038.

Zhang, C. X., Zhang, Y., Wang , X., Tang, Z. M., & Lu, Z. H. (2003). Hyper-Rayleigh Scattering of Protein-Modified Gold Nanoparticles. Analytical Biochemistry, 320, 136-140.

Artini, I. A. (2013). Peranan Nanopartikel dalam Penatalaksanaan Kanker di Era Targeting Therapy. Indonesian Journal of Cancer, Vol. 7, No. 3.

Bawarski, W. E., Chidlowsky, E., Bharali, D. J., & Mousa, S. A. (2008). Review Article: Pharmacology, Emerging Nanopharmaceutical. Nanomedicine: Nanotechnology, Biology, and Medicine 4, 273-282.

Buzea, C., Blandino, I. I., & Robbie, K. (2007). Nanomaterials and Nanoparticles: Sources and toxicity. Biointerphases, Vol. 2, Issue 4, MR17-MR172.

Dewi, G. T., & Hendrati, L. Y. (2015). Analisis Resiko Kanker Paayudara berdasarkan Riwayat Pemakaian Kontrasepsi Hormonal dan Usia Menarche. Epidemiologi, Vol. 3, No. 1.

Gibbs, J. B. (2000). Mechanism-Based target Identification and Drug Discovery in Cancer Research. Science.

Halid, N. A., & et al. (2017). Profil Klirens Konjugat Nanopartikel Emas Radioaktif (198Au)-poliamidoamin Generasi 4-nimotuzumab: Radiofarmaka Potensial sebagai Agen Theranostic. Pharmaciana, Vol. 7, No. 2, ISSN: 2088-4559, e-ISSN: 2477-0256, 239-248.

Inggriani, A. S., & Husni, P. (2017). Artikel Review: Formulasi Nanopartikel untuk Terapi Kanker. Farmaka, Vol. 14, No. 1, 127-135.

Johnson, E., Seachrist, D. D., DeLeon-Rodriguez, C. M., Lozada, K. L., Miedler, J., Abdul-Karim, F. W., et al. (2010). HER2/ErbB2-induced Breast Cancer Cell Migration and Invasion Require p120 Catenin Activation of Rac1 and Cdc42. Journal of Biological Chemistry, 285(38): 29491-29501.

Liu, Y., Liu, Y., Mernaugh, R. L., & Zeng, X. (2009). Single Chain Fragment Variable Recombinant Antibody Functionalized Gold Nanoparticles for a Highly Sensitive Colorimetric Immunoassay. Biosensors and Bioelectronics, 24, 2853-2857.

Martien, R., Adhyatmika, Irianto, I. D., Farida, V., & Sari, D. P. (2012). Perkembangan Teknologi Nanopartikel sebagai Sistem Penghantaran Obat. Majalah Farmaseutik, Vol.8, No. 1, 133-144.

Merisko-Liversidge, E. M., & Liversidge, G. G. (2008). Drug Nanoparticles: Formulating Poorly Water-Soluble Compounds. Toxicologic Pathology, 36, ISSN: 0192-6233, e-ISSN: 1533-1601, 43-48.

Nie, S. (2010). Understanding and Overcoming Major Barriers in Cancer Nanomedicine. Nanomedicine (Lond.), 5(4).

Peterson, E., Owens, S. M., & Henry, R. L. (2006). Monoclonal Antibody form and Function: Manufacturing The Right Antibodies for Treating Drug Abuse. AAPS Journal, 8(2): E383-E390.

Pohlmann, P. R., & Mernaugh, R. (2009). Resistance to Trastuzumab in Breast Cancer. Clinical Cancer Research, 15(24): 7479-7491.

Sastyarina et al. (2017). Kajian Dendrimer (Poly)amidoamine (PAMAM) Generasi 4 sebagai Template dalam Pembentukan Nanopartikel secara In Silico. Journal of Tropical Pharmacy and Chemistry, Vol. 4, No. 1, p-ISSN: 2087--7099, e-ISSN: 2407-6090.

Shen et al. (2005). Engineered Recombinant Single Chain Fragment Variable Antibodi For Immonosensors. Anal Chem, 77(21): 6834-6842.

Short, J. M., Waldron, R. A., Boyle, W., Chang, C., Anderson, C., Melnick, M., et al. (2005). Antibody Structure. Bioatla, 1-4.

Sihombing, M., & Sapardin, A. N. (2014). Faktor Risiko Tumor Payudara pada Perempuan Umur 25-65 tahun di Lima Kelurahan Kecamatan Bogor Tengah. Jurnal Kesehatan Reproduksi, ISSN: 2087-703X, eISSN: 2354-8762.

Spector, N., Xia, W., El-Hariry, I., Yarden, Y., & Bacus, S. (2007). Review: HER2 Therapy. Small Molecule HER-2 Tyrosine Kinase Inhibitors. Breast Cancer Research, 9(2):205.

Zeng, X., Shen, Z., & Mernaugh, R. (2012). Recombinant Antibodies and Their Use in Biosensors. Anal Bioanal Chem, 402(10): 3027-3038.

Zhang, C. X., Zhang, Y., Wang , X., Tang, Z. M., & Lu, Z. H. (2003). Hyper-Rayleigh Scattering of Protein-Modified Gold Nanoparticles. Analytical Biochemistry, 320, 136-140.




DOI: https://doi.org/10.24198/jf.v16i2.17534

DOI (PDF (Bahasa Indonesia)): https://doi.org/10.24198/jf.v16i2.17534.g8760

Article metrics

Abstract views : 0 | views : 0

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 NADA FADHILAH